Actively Recruiting
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
Led by Shu Wang · Updated on 2024-12-02
8077
Participants Needed
1
Research Sites
678 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and easy recurrence and metastasis. The emergence of HER2 targeted drugs has greatly improved the prognosis and survival of such patients. At present, for HER2 positive breast cancer patients with negative lymph nodes, chemotherapy drugs combined with trastuzumab is the current standard treatment scheme, and in most cases, chemotherapy uses a combination of two drugs, while the main beneficiaries of the trastuzumab and pertuzumab are concentrated in the group of patients with positive lymph nodes. Can targeted therapy be used to reduce the progression of chemotherapy and further achieve efficient and low toxicity strategies. It is planned to explore the efficacy and safety of T1-T2, HER2 positive early breast cancer patients with negative lymph nodes to achieve chemotherapy reduction based on risk stratification.
CONDITIONS
Official Title
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Treated at Peking University People's Hospital with radical breast cancer surgery and hospitalization records
- Postoperative invasive breast cancer confirmed as HER2 positive, pathological stage T1c, N0 with high-risk factors (grade 3 or hormone receptor negative)
- Or pathological stage T2, N0 without high-risk factors (grade 3 or hormone receptor negative)
- Signed agreement to participate in the PKUPH Breast Disease Cohort study at Peking University People's Hospital
You will not qualify if you...
- Missing clinical pathological data such as imaging or pathological reports
- Received preoperative neoadjuvant therapy
- Diagnosed with metastatic or bilateral breast cancer
- Did not undergo curative surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
Y
yuan peng, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here